3-(1,1-difluoroethoxy)pyridin-2-amine | 1268522-09-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(1,1-difluoroethoxy)pyridin-2-amine
• 英文别名: 2-Pyridinamine, 3-(1,1-difluoroethoxy)-
• CAS: 1268522-09-3
• 化学式: C₇H₈F₂N₂O
• mdl: MFCD18632741
• 分子量: 174.15
• InChiKey: HPOPDOYTTVAQOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-3-羟基吡啶 在 palladium 10% on activated carbon 氢气 、 potassium hydroxide 作用下， 以 乙醇 、 乙腈 为溶剂， 20.0 ℃ 、310.27 kPa 条件下， 反应 23.5h， 生成 3-(1,1-difluoroethoxy)pyridin-2-amine
  参考文献：
  名称：

  [EN] PYRIMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES
  [FR] PYRIMIDONES UTILISABLES EN VUE DU TRAITEMENT D'AFFECTIONS ASSOCIÉES AUX CANAUX POTASSIQUES

  摘要：

  公开号：

  WO2012038850A8

文献信息

• Pyrimidones for Treatment of Potassium Channel Related Diseases
  申请人：Sakurada Isao

  公开号：US20130184294A1

  公开（公告）日：2013-07-18

  The present invention relates to compounds of Formula I as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.

  本发明涉及公式I所述的化合物或其药学上可接受的盐，包括公式I化合物或其药学上可接受的盐的制药组合物以及治疗中枢神经系统疾病、失调或病症的方法，包括双相情感障碍、抑郁症、焦虑症、认知障碍、疼痛障碍、泌尿生殖系统障碍和癫痫等其他在此处讨论的疾病、失调或病症，作为单一治疗或与另一种活性药物成分联合使用。
• [EN] PYRIMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES<br/>[FR] PYRIMIDONES UTILISABLES EN VUE DU TRAITEMENT D'AFFECTIONS ASSOCIÉES AUX CANAUX POTASSIQUES
  申请人：PFIZER

  公开号：WO2012038850A8

  公开（公告）日：2012-11-01
• PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES
  申请人：Pfizer Inc.

  公开号：EP2619202A1

  公开（公告）日：2013-07-31
• [EN] PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES<br/>[FR] PYRIMIDONES UTILISABLES EN VUE DU TRAITEMENT D'AFFECTIONS ASSOCIÉES AUX CANAUX POTASSIQUES
  申请人：PFIZER

  公开号：WO2012038850A1

  公开（公告）日：2012-03-29

  The present invention relates to compounds of Formula I as described herein or a 1 pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.
• Synthesis of α,α-Difluoroethyl Aryl and Heteroaryl Ethers
  作者：Eddie Yang、Matthew R. Reese、John M. Humphrey

  DOI：10.1021/ol301696x

  日期：2012.8.3

  Fluorine plays a critical role in modern medicinal chemistry due to its unique properties, and new methods for its incorporation into target molecules are of high interest. An efficient new method for the preparation of aryl-alpha,alpha-difluoroethyl ethers (4) via addition of aryl and heteroaryl alcohols (1) to commercially available 2-bromo-1,1-difluoroethene (2) and subsequent hydrogenolysis is presented. This procedure is an attractive alternative to existing methods that employ harshly reactive fluorinating systems such as xenon difluoride and hydrogen fluoride.